清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy of Renin-Angiotensin System Inhibitors in Long-Term Oncologic Outcomes of Patients With Stage II/III Colon Cancer and Hypertension: A Target Trial Emulation

医学 结直肠癌 内科学 肿瘤科 阶段(地层学) 随机对照试验 回顾性队列研究 总体生存率 队列 倾向得分匹配 腺癌 癌症 临床试验 结肠腺癌 队列研究 病历 癌症登记处 外科 大肠腺癌 多中心试验 仿真 多元分析 存活率
作者
K Chen,Donghao Xu,Z G Zhang,F Y Liang,G D He,Jianmin Xu,Q Y Feng
出处
期刊:JCO oncology practice [Lippincott Williams & Wilkins]
卷期号:: OP2501296-OP2501296 被引量:1
标识
DOI:10.1200/op-25-01296
摘要

PURPOSE Renin-angiotensin system inhibitors (RASIs) have been reported to exert anticancer effects. However, there is still a lack of persuasive evidence for their role in improving postoperative long-term oncologic outcomes of colorectal cancer. This retrospective cohort study emulated a hypothetical randomized controlled trial to evaluate the efficacy of RASIs in improving postoperative long-term oncologic outcomes of patients with stage II/III colon cancer and hypertension. METHODS Patients were consecutively enrolled from multicenter databases, which contained data from medical centers in Shanghai, China. Eligible criteria were adults with radical resected stage II or III colon adenocarcinoma and hypertension. Eligible patients were classified into the RASI group or the no-RASI group, and propensity score was matched at a 1:1 ratio. The primary outcome was the 3-year disease-free survival (DFS) rate. RESULTS From 2,640 eligible patients, 2,292 were included in the primary analysis after matching: 1,146 in the RASI group and 1,146 in the no-RASI group. The median follow-up time was 46.3 months. The RASI group had a higher 3-year DFS rate (83.4% v 78.3%; P = .001; hazard ratio [HR], 0.736 [95% CI, 0.617 to 0.878]). The RASI group also had a lower 3-year distant metastasis rate (15.6% v 20.5%; P < .001; HR, 0.717 [95% CI, 0.596 to 0.863]) and a higher 3-year overall survival rate (92.4% v 89.6%; P = .001; HR, 0.682 [95% CI, 0.539 to 0.864]). CONCLUSION RASIs may improve the postoperative long-term oncologic outcomes for patients with stage II/III colon cancer and hypertension.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
TingtingGZ发布了新的文献求助30
2秒前
幸福猎豹完成签到,获得积分10
19秒前
19秒前
24秒前
28秒前
cy0824完成签到 ,获得积分10
32秒前
复杂亦瑶完成签到,获得积分10
39秒前
肉袒牵洋完成签到 ,获得积分10
43秒前
小二郎的应助被兰斯洛特117采纳,获得10
45秒前
Criminology34的应助被科研通管家采纳,获得10
45秒前
Criminology34的应助被科研通管家采纳,获得10
45秒前
47秒前
俊秀的凡蕾完成签到,获得积分10
1分钟前
1分钟前
1分钟前
刻苦续完成签到,获得积分10
1分钟前
1分钟前
ZXneuro完成签到,获得积分10
1分钟前
1分钟前
TingtingGZ发布了新的文献求助10
1分钟前
在水一方的应助被WebCasa采纳,获得50
1分钟前
1分钟前
1分钟前
2分钟前
2分钟前
小巧慕儿完成签到,获得积分10
2分钟前
动听的山槐完成签到,获得积分10
2分钟前
2分钟前
Criminology34的应助被科研通管家采纳,获得10
2分钟前
Criminology34的应助被科研通管家采纳,获得10
2分钟前
Criminology34的应助被科研通管家采纳,获得10
2分钟前
小二郎的应助被科研通管家采纳,获得10
2分钟前
Criminology34的应助被科研通管家采纳,获得10
2分钟前
2分钟前
华仔的应助被xun采纳,获得10
2分钟前
2分钟前
正直的剑愁完成签到,获得积分10
3分钟前
WebCasa发布了新的文献求助50
3分钟前
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173194
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780461
捐赠科研通 7767279
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476682